Mechanisms of chemotherapeutic-induced hearing loss and otoprotection

Adrien Eshraghi, Michael Bublik, Thomas R Van De Water

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Cisplatin (CDDP) and carboplatin are highly effective chemotherapeutic agents with ototoxic side effects that limit their efficacy. Formation of reactive oxygen species (ROS) in CDDP-exposed cochlear tissues is involved in ototoxic action of the CDDP on hair cells. Downstream targets of ROS are cell death mediator molecules, for example, p53 and activated caspases. The efficacy of several otoprotective compounds is discussed in relationship to their impact on protection of hearing and potential for interfering with the chemotherapeutic treatment of cancer.

Original languageEnglish
Pages (from-to)125-130
Number of pages6
JournalDrug Discovery Today: Disease Mechanisms
Volume3
Issue number1
DOIs
StatePublished - Jul 19 2006

Fingerprint

Hearing Loss
Reactive Oxygen Species
Carboplatin
Cochlea
Caspases
Cisplatin
Hearing
Cell Death
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine

Cite this

Mechanisms of chemotherapeutic-induced hearing loss and otoprotection. / Eshraghi, Adrien; Bublik, Michael; Van De Water, Thomas R.

In: Drug Discovery Today: Disease Mechanisms, Vol. 3, No. 1, 19.07.2006, p. 125-130.

Research output: Contribution to journalArticle

Eshraghi, Adrien ; Bublik, Michael ; Van De Water, Thomas R. / Mechanisms of chemotherapeutic-induced hearing loss and otoprotection. In: Drug Discovery Today: Disease Mechanisms. 2006 ; Vol. 3, No. 1. pp. 125-130.
@article{0c47b674cb344a4696a43b9d944e2df0,
title = "Mechanisms of chemotherapeutic-induced hearing loss and otoprotection",
abstract = "Cisplatin (CDDP) and carboplatin are highly effective chemotherapeutic agents with ototoxic side effects that limit their efficacy. Formation of reactive oxygen species (ROS) in CDDP-exposed cochlear tissues is involved in ototoxic action of the CDDP on hair cells. Downstream targets of ROS are cell death mediator molecules, for example, p53 and activated caspases. The efficacy of several otoprotective compounds is discussed in relationship to their impact on protection of hearing and potential for interfering with the chemotherapeutic treatment of cancer.",
author = "Adrien Eshraghi and Michael Bublik and {Van De Water}, {Thomas R}",
year = "2006",
month = "7",
day = "19",
doi = "10.1016/j.ddmec.2006.03.007",
language = "English",
volume = "3",
pages = "125--130",
journal = "Drug Discovery Today: Disease Mechanisms",
issn = "1740-6765",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Mechanisms of chemotherapeutic-induced hearing loss and otoprotection

AU - Eshraghi, Adrien

AU - Bublik, Michael

AU - Van De Water, Thomas R

PY - 2006/7/19

Y1 - 2006/7/19

N2 - Cisplatin (CDDP) and carboplatin are highly effective chemotherapeutic agents with ototoxic side effects that limit their efficacy. Formation of reactive oxygen species (ROS) in CDDP-exposed cochlear tissues is involved in ototoxic action of the CDDP on hair cells. Downstream targets of ROS are cell death mediator molecules, for example, p53 and activated caspases. The efficacy of several otoprotective compounds is discussed in relationship to their impact on protection of hearing and potential for interfering with the chemotherapeutic treatment of cancer.

AB - Cisplatin (CDDP) and carboplatin are highly effective chemotherapeutic agents with ototoxic side effects that limit their efficacy. Formation of reactive oxygen species (ROS) in CDDP-exposed cochlear tissues is involved in ototoxic action of the CDDP on hair cells. Downstream targets of ROS are cell death mediator molecules, for example, p53 and activated caspases. The efficacy of several otoprotective compounds is discussed in relationship to their impact on protection of hearing and potential for interfering with the chemotherapeutic treatment of cancer.

UR - http://www.scopus.com/inward/record.url?scp=33745894990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745894990&partnerID=8YFLogxK

U2 - 10.1016/j.ddmec.2006.03.007

DO - 10.1016/j.ddmec.2006.03.007

M3 - Article

AN - SCOPUS:33745894990

VL - 3

SP - 125

EP - 130

JO - Drug Discovery Today: Disease Mechanisms

JF - Drug Discovery Today: Disease Mechanisms

SN - 1740-6765

IS - 1

ER -